Biolargo Stock Performance
| BLGO Stock | USD 0.25 0.01 3.85% |
On a scale of 0 to 100, BioLargo holds a performance score of 6. The firm shows a Beta (market volatility) of 0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioLargo's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioLargo is expected to be smaller as well. Please check BioLargo's treynor ratio and the relationship between the semi variance and period momentum indicator , to make a quick decision on whether BioLargo's price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BioLargo are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting technical and fundamental indicators, BioLargo displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 716 K | |
| Total Cashflows From Investing Activities | -34 K |
BioLargo |
BioLargo Relative Risk vs. Return Landscape
If you would invest 21.00 in BioLargo on November 3, 2024 and sell it today you would earn a total of 4.00 from holding BioLargo or generate 19.05% return on investment over 90 days. BioLargo is currently generating 0.4426% in daily expected returns and assumes 5.6476% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of otc stocks are less volatile than BioLargo, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLargo Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLargo's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as BioLargo, and traders can use it to determine the average amount a BioLargo's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0784
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BLGO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.65 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average BioLargo is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLargo by adding it to a well-diversified portfolio.
BioLargo Fundamentals Growth
BioLargo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BioLargo, and BioLargo fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLargo OTC Stock performance.
| Return On Equity | -3.63 | |||
| Return On Asset | -0.69 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.16) % | |||
| Current Valuation | 52.87 M | |||
| Shares Outstanding | 275.42 M | |||
| Price To Earning | (4.54) X | |||
| Price To Book | 10.61 X | |||
| Price To Sales | 11.52 X | |||
| Revenue | 2.53 M | |||
| EBITDA | (6.64 M) | |||
| Cash And Equivalents | 1.23 M | |||
| Total Debt | 367 K | |||
| Debt To Equity | 0.72 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.94 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 3.02 M | |||
| Retained Earnings | (89.68 M) | |||
| Current Asset | 1.87 M | |||
| Current Liabilities | 831 K | |||
About BioLargo Performance
By examining BioLargo's fundamental ratios, stakeholders can obtain critical insights into BioLargo's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BioLargo is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.Things to note about BioLargo performance evaluation
Checking the ongoing alerts about BioLargo for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BioLargo help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLargo had very high historical volatility over the last 90 days | |
| BioLargo has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 1.1 M. | |
| BioLargo currently holds about 1.23 M in cash with (3.94 M) of positive cash flow from operations. | |
| Roughly 15.0% of the company shares are held by company insiders |
- Analyzing BioLargo's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLargo's stock is overvalued or undervalued compared to its peers.
- Examining BioLargo's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLargo's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLargo's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of BioLargo's otc stock. These opinions can provide insight into BioLargo's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.